Kornimate/medical-research-clean huggingface dataset:
efficacy of three online well-being programs to improve work-related outcomes

Conditions: Well-being

Summary: participants will be randomly assigned between three well-being programs, and assessed with questionnaires before and after the 8-week program, as well as 1-month after the end of the program.

participants will be randomly assigned between three different well-being programs, with each program lasting 8-weeks and taking place on a simplified research version of the happify platform. well-being programs include the unchanged happify platform, a version of the happify platform that is designed to engage with specific activities but does not aim to promote positive emotion or reduce negative emotion (i.e., placebo condition), and a version of the happify platform that encourages thinking about well-being through quizzes and polls without providing any instructions for promotion (i.e., wait-list control). participants will be asked to complete questionnaires before and after the 8-week program, as well as a 1-month follow-up questionnaire after the program is complete, at which point study participation will end.

Eligibility criteria:
inclusion criteria: * no prior experience on the happify platform (new user registration) * full-time employment exclusion criteria: * none
converting from ropinirole immediate release (ir) to ropinirole controlled-release for rls (restless legs syndrome)

Conditions: Restless Legs Syndrome; Restless Legs Syndrome (RLS)

Summary: this is a multi-center, phase iii study to evaluate the safety and tolerability of proposed dose conversion recommendations for rls subjects converting from ropinirole immediate release to ropinirole controlled-release for rls.


Eligibility criteria:
inclusion criteria: * diagnosis of rls using irls study group (irlssg) diagnostic criteria. * subjects currently being treated for rls with a stable dose (for at least 2 weeks) of ropinirole ir given once daily. * subjects with rls symptoms during both the evening and night or night time only. * subjects who have given written informed consent to participate. exclusion criteria: * subjects who require treatment of daytime rls symptoms. * signs of secondary rls, serum ferritin level less than 10 mcg/l. * movement disorders, clinically significant or unstable medical conditions. * abnormal labs, electrocardiogram (ecg) or physical findings. * receiving prohibited medications. * sleeping habits incompatible with study design. * intolerance to ropinirole or other dopamine agonist. * pregnant or lactating. * women of child-bearing potential who are not practicing an acceptable method of birth control.

Keywords: rls ropinirole restless legs syndrome
analysis of volatile organic compounds by electronic noses in hospitalised patients for an infection by sars-cov-2 (covid-19)

Conditions: COVID-19

Summary: the study of volatile organic compounds (vocs) detected in exhaled air is an innovative research area for respiratory diseases. this analysis can be done by the technique of electronic nose, simpler and faster, which provides an idea of the general profile of the vocs without identifying them. the vocs in exhaled air in patients hospitalized for covid-19 infection are analysed in this study, using electronic noses.


Eligibility criteria:
inclusion criteria: * patients infected by sars-cov-2 whose medical condition warrants hospitalisation (out of intensive care) for oxygen therapy less or equal to 4 l/min * patients must be 18 years of age or older * fluent in the french language * have signed a consent form * being affiliated with healthcare insurance exclusion criteria: * pregnant woman * patient deprived of liberty by judicial or administrative decision
doppler sonography, mr venography, plethysmography for the diagnosis of ccsvi

Conditions: Chronic Cerebrospinal Venous Insufficiency

Summary: this study is aimed at evaluation of diagnostic value of doppler sonography, mr venography and air-plethysmography for the assessment of abnormalities in the internal jugular veins, with catheter venography as the reference test.


Eligibility criteria:
1. patients group inclusion criteria: * confirmed diagnosis of multiple sclerosis exclusion criteria: * coexisting another neurologic pathology (e.g. stroke, parkinson disease) * significant stenosis of carotid or vertebral arteries * other significant abnormalities of blood vessels of the upper part of the body * tricuspid valve incompetence * allergy to iodine contrast dye * chronic renal failure * pregnancy * other severe comorbidities or significant abnormalities in standard lab tests 2. healthy volunteers. inclusion criteria: * none exclusion criteria: * confirmed diagnosis of multiple sclerosis or related pathologies (cis, nmo) * coexisting another neurologic pathology (e.g. stroke, parkinson disease) * significant stenosis of carotid or vertebral arteries * other significant abnormalities of blood vessels of the upper part of the body * tricuspid valve incompetence

Keywords: vascular malformations in the internal jugular veins
observational prospective study on patients with symptomatic uterine fibroids treated with vizablate® intrauterine-ultrasound guided rf ablation

Conditions: Menorrhagia; Leiomyoma; Uterine Fibroids; Uterine Fibroma; Uterine Neoplasms

Summary: study is intended to evaluate the one-year safety and clinical status of patients treated for symptomatic uterine fibroids with the vizablate intrauterine-ultrasound guided radio frequency (rf) ablation system. particular attention will be directed to recording safety outcomes including incidence of uterine cavity synechiae. in addition, information on quality of life will be collected. overall study duration (first patient enrolled through last patient exit) will be comprised of approximately 12 months of patient enrollment up to 1 month for scheduling of treatment, and 12 months of follow-up, for a total duration of up to 25 months. study duration for an individual patient, once enrolled, will be approximately 1 month for baseline observations and treatment scheduling, and 12 months for follow up after treatment for a total duration of approximately 13 months.

in this single-arm study, subjects who receive transcervical intrauterine-ultrasound guided rf ablation of symptomatic uterine fibroids with the vizablate® system will be assessed with 3d pelvic sonography with contrast, hysteroscopy, and quality of life questionnaires. overall study duration (first patient enrolled through last patient exit) will be comprised of approximately 12 months of patient enrollment up to 1 month for scheduling of treatment, and 12 months of follow-up, for a total duration of up to 25 months. study duration for an individual patient, once enrolled, will be approximately 1 month for baseline observations and treatment scheduling, and 12 months for follow up after treatment for a total duration of approximately 13 months.

Eligibility criteria:
inclusion criteria: * 28 years of age or older * indication for transcervical treatment of uterine fibroids associated with menorrhagia * willingness to participate in the study, to attend all follow-up visits and undergo all study assessments, and to sign the informed consent form * presence of submucosal and/or intramural fibroids exclusion criteria: * pregnancy * ≥40 years of age with desire for current or future fertility, unless the estimated risk/benefit ratio has been determined to be more favorable to future pregnancy than standard therapy * non-sterilized patients \< 40 years of age, unless the estimated risk/benefit ratio has been determined to be more favorable to future pregnancy than standard therapy * active pelvic infection, known or suspected gynecologic malignancy or premalignant condition * presence of tubal implant for sterilization * previous pelvic irradiation * endometrial cavity length, including endocervical canal, \< 4.5 cm * any abnormality of the vagina or uterine cavity that, in the judgment of the investigator obstructs access of the vizablate handpiece to the endometrial cavity * presence of cardiac pacemaker or other active implant * post-menopausal

Keywords: menorrhagia leiomyoma uterine fibroids
building resiliency and vital equity (brave) project: understanding native americans' perceptions/beliefs about covid-19 testing and vaccination study

Conditions: Covid19 Virus Infection

Summary: the building resilience and vital equity (brave) project seeks to partner with american indian tribal communities in north carolina to establish covid-19 services and resources for american indian communities. the goal of this study is to 1) understand the barriers and social implications of covid19 testing and vaccination among american indians by designing and implementing culturally sensitive survey tools and intervention materials; 2) implement brave outreach and testing interventions to increase testing in american indian communities; 3) analyze data and share back with tribal communities to improve perceptions of covid-19 testing in the ai community and decrease in vaccine hesitancy.


Eligibility criteria:
inclusion criteria: - self reports as native american or american indian exclusion criteria: * does not self-report as native american or american indian

Keywords: covid-19 testing
the effect of tight glycemic control on surgical site infection rates in patients undergoing open heart surgery

Conditions: Diabetes; Hyperglycemia; Surgical Site Infection

Summary: the purpose of this study was to investigate the effects of three different glycemic treatment conditions (tight, conventional, and standard) in the intraoperative period on: 1) postoperative surgical site infections, and 2) postoperative procalcitonin, and c-reactive protein levels in patients undergoing open-heart surgery. secondary aims of the study were to investigate the effects of the three glycemic treatment conditions on: 1) intraoperative blood glucose; 2) intraoperative glycemic stability; and 3) intensive care unit length of stay, in patients undergoing open-heart surgery.

an experimental design with a multilevel, single factor, within-subjects design was utilized. patients were nested within anesthesia provider teams. the design was counterbalanced by means of a latin square, where each of three anesthesia provider teams dispensed each of three glycemic treatment conditions once.

Eligibility criteria:
inclusion criteria: * over the age of 21 * on cardiopulmonary bypass or off cardiopulmonary * elective or urgent coronary artery bypass graft (cabg) surgery * cabg with or without combined valve surgery * valve surgery exclusion criteria: * chronically immunosuppressed * suffered from end-stage organ disease * currently had active infections * underwent emergent or salvage cabg surgery * had an implanted insulin pump * were in another interventional clinical trial.

Keywords: glycemic control
gp96 heat shock protein-peptide complex vaccine in treating patients with liver cancer

Conditions: Liver Cancer

Summary: this trial is to further study the safety and effectiveness of autologous gp96 treatment of liver cancer on the basis of preliminary work

rationale: heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells. overall goals: - to evaluate the safety and induction of anti-tumor immunity by administration of an immunogenic human tumor cell vaccine, and assess immune response in relation to clinical outcome. primary aim: - to further evaluate effectiveness of autologous gp96 treatment of liver cancer on the basis of preliminary work. secondary aims: to study the immune response to vaccination, to monitor clinical responses , to further the safety of vaccine.

Eligibility criteria:
inclusion criteria: 1. able to read and understand the informed consent document; must sign the informed consent; 2. aged 18 to 75 years old , sex is not limited; 3. must have undergone radical resection;ajcc tnm ii、iii、iv. 4. availability of at least 1g tumor sample; 5. adequate bone marrow function including the absence of lymphopenia (anc \> 1,500/ mm3; hemoglobin \> 10g/dl ; platelet count \>100,000/mm3), adequate liver function (serum glutamic oxaloacetic transaminase/ aspartate aminotransferase \[ast\], alanine amino transferase \[alt\] \<2.5 times institutional upper limit of normals \[iulns\] ), and adequate renal function (bun and creatinine \<1.5 times iulns) 6. agree to surgical indications of heart \& lung and without the coagulation system disease 7. patients could not have received previous anti-cancer treat before 4 weeks of gp96 treatment； exclusion criteria: 1. inability to comply with study-related procedures 2. unavailability of at least 6 doses of vaccine 3. severe allergies 4. unstable or severe intercurrent medical conditions 5. current diagnosis of human immunodeficiency virus and patients with active uncontrolled infection. 6. patients with any systemic disease needed to be treated with immunosuppressant or corticosteroids. 7. female patients who are pregnant or breastfeeding 8. steroidal drugs are currently being used systemically.
phase iv study of chronic infusional epoprostenol for severe primary pulmonary hypertension

Conditions: Hypertension, Pulmonary

Summary: objectives: i. provide epoprostenol (flolan, prostaglandin i2) by chronic infusion to patients with severe primary pulmonary hypertension for whom no alternative therapy is available. ii. obtain additional safety information on continuous infusion epoprostenol. iii. obtain additional information on economic resource health consumption.

protocol outline: patients are treated with a chronic continuous infusion of epoprostenol. the highest tolerated infusion rate is determined for each patient by gradually increasing the rate until the target dose is reached or the patient experiences at least 1 dose-limiting effect. patients are subsequently treated with a chronic continuous infusion, beginning at a rate below the highest tolerated rate. attempts are made to increase the dose to the highest tolerated rate over the first 72 hours.

Eligibility criteria:
protocol entry criteria: * severe primary pulmonary hypertension * able to prepare and self-administer medication

Keywords: cardiovascular and respiratory diseases hypertensive disorder primary pulmonary hypertension rare disease
a multifaceted prompting intervention for urban children with asthma

Conditions: Asthma

Summary: the overall goal of this project is to evaluate whether a multifaceted prompting intervention, administered in the urban primary care office setting, reduces morbidity among urban children with asthma. this study builds on our experience with a pilot study in two urban continuity clinics, in which we found that prompting clinicians about asthma severity and care guidelines at the time of an office visit resulted in improved preventive care delivery to inner-city children. this type of prompting program has the potential to substantially improve care for impoverished children with asthma, and we propose to establish: 1) whether these findings can be replicated in a similar study including a larger sample of urban children from different types of practices, and 2) whether the positive effects can be enhanced by more specific prompting directed towards both the provider and the caregiver and by providing practice-level supports and feedback. we hypothesize that children receiving a multifaceted prompting intervention (mpi) will experience less asthma-related morbidity (defined by symptom-free days at the 2-month follow-up) compared to children receiving usual care. our secondary hypothesis is that children receiving the mpi will receive improved preventive asthma care (defined by guideline-based corrective actions taken at the index visit) compared to children receiving usual care.


Eligibility criteria:
inclusion criteria: * physician-diagnosed asthma * mild persistent or more severe asthma severity, or poor asthma control * age \>2 and \<12 years. * parent or caregiver must give permission to the study, and children \>7 will must provide assent. exclusion criteria: * inability to speak and understand english or spanish * no access to a working phone for follow-up surveys * the child having other significant medical conditions, * children in foster care or other situations in which consent cannot be obtained from a guardian. * prior enrollment in the study. * child will not be seen by a physician or nurse practitioner during their visit
space maintainers effects on oral mi̇croflora

Conditions: Orthodontic Appliance Complication; Lactobacillus Infection; Dental Caries in Children; Streptococcus, Other Specified Group

Summary: space maintainers are used to preserve the space after premature loss of teeth but they could effect some factors that play a role in caries formation. the research aimed to assess the impacts of removable and fixed space maintainers on the salivary ph, flow rate, and streptococcus mutans, lactobacillus carriage.

although the usage of space maintainers can reduce the severity of problems that arise from the early loss of teeth, there are concerns regarding the impact of fixed and removable appliances on factors that can lead to dental caries. all space maintainer appliances are plaque retentive since bands and brackets increase the retention of plaque and food on tooth surfaces, reduce the clearance of plaque by saliva and make conventional oral hygiene for plaque removal more difficult, therefore, they may cause caries development.space maintainers can favor caries formation by changing the oral microflora. patients aged between 4-10 years, each of whom had an indication for a fixed (n=19) or removable space maintainer (n=19), were enrolled in this research. the salivary ph, saliva flow rate, streptococcus mutans and lactobacillus counts in saliva were measured just prior to the application of space maintainers (baseline-t0) and in the course of the follow-up; at the 1st (t1), 3rd (t2), and 6th (t3) months. the wilcoxon, mann-whithney u test and friedman tests were used for statistical analyses.

Eligibility criteria:
inclusion criteria: * the present research was conducted on 38 patients aged between 4-10 years, each of whom had an indication for a fixed or removable space maintainer. exclusion criteria: * patients with a medical history that could influence microorganism carriage, including systemic disease, immunosuppression and the usage of antibiotics in the preceding 15 days, were excluded from the research

Keywords: space maintainers streptococcus mutans lactobacillus salivary flow salivary ph
pilot study evaluating the success (= safe decannulation) of a standardized tracheotomy weaning procedure in brain-injury's patients

Conditions: Tracheostomy; Brain Injuries

Summary: tracheotomy weaning and decannulation are one of the important problems in the neurosurgical care unit. aside from medical, psychological, sociological, economical and ethics problems, tracheotomy increases the duration of the hospital stay and conditions the secondarily future medical care (better re-education after the injury). however, according to investigators practices, that patients who were decannulated with success can go into a secondary care residence more easily. this research will demonstrate that all patients included can be decannulated without risk of a new recannulation in the 96 hours.

brain injury patients with alertness disorders, wake-up delay and / or swallowing disorders, frequently have a tracheotomy. this tracheotomy is often a problem when it comes to find a bed in a secondary care unit, which is better adapted to the patient rehabilitation. unfortunately, there is little room to accept this type of patient. it is therefore appropriate to do the weaning during the neurosurgery unit stay. bibliographical studies indicate few recommendations as to weaning outside intensive care units. in the neurosurgery units at the university hospital of bordeaux, during 3 years (2014-2016), investigators have practiced 29 decannulations without recannulation, over 37 brain injury patients, with a multi-professional team (neurosurgeon, physiotherapist, nurse, caregiver...) to produce a weaning process. from where investigators hypothesis: using a multi-professional weaning process, checking the patient's stability during the different weaning steps, can lead to decide to decannulate or not without any risk.

Eligibility criteria:
inclusion criteria: * age at least 18 years old * brain-injury disease * tracheotomy act while in neurosurgery or reanimation stay * no artificial ventilation * medical cover * free, informed and express consent by the patient or his legal representative (no later than the day after the inclusion and before all exam necessary for the research) exclusion criteria: malnutrition (defines by the age) : * age \< 70 years old: body mass index (b.d.i.) \<16 kg/m² or albuminemia \<20 g/l * age \> 70 years old: body mass index (b.d.i.) \<18 kg/m² or albuminemia \<30 g/l

Keywords: tracheostomy decannulation rehabilitation brain injury neurosurgery
prevention of remifentanil-induced postoperative hyperalgesia with intravenous ibuprofen

Conditions: Ibuprofen; Remifentanil; Hyperalgesia; Pain, Postoperative

Summary: postoperative hyperalgesia has been reported after intraoperative administration of small or high-dose remifentanil. cyclooxygenase inhibitor exhibit preventive effects on the development of opioid-induced hyperalgesia. the aim of this study is to evaluate the preventive effect of intravenous ibuprofen (caldolor®) on remifentanil-induced hyperalgesia


Eligibility criteria:
inclusion criteria: * adult patients scheduled for elective pancreaticoduodenectomy exclusion criteria: * patients with chronic pain * patients with psychiatric disease * patients with nonsteroidal antiinflammatory drugs allergy * patients with renail dysfunction * history of drug addiction * pregnant patient * inability to use a pca device